The ABCB6 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of human Jurkat T-lymphocyte cells in which the ABCB6 gene has been disrupted. This loss-of-function model enables investigation of ABCB6-dependent processes without the constraints of clonal selection. The polyclonal format offers a representative heterogeneous knockout pool, ideal for functional genomic screening and biochemical assays where bulk population analysis is desired.
Jurkat cells are an immortalized T-cell line derived from the peripheral blood of a patient with acute T-cell leukemia. They serve as a widely used model for T-cell signaling, apoptosis, and leukemia biology. Their robust growth and well-characterized signaling networks make them a reliable host for studying gene function in the context of T-cell malignancies. The Jurkat background provides a relevant platform to evaluate how ABCB6 disruption influences heme metabolism and drug sensitivity in leukemic T cells.
ABCB6 encodes a mitochondrial outer membrane transporter that mediates the ATP-dependent import of coproporphyrin III into the mitochondrial intermembrane space, a critical step in heme biosynthesis. It also functions in porphyrin efflux and contributes to cellular resistance against certain chemotherapeutic agents. ABCB6 is transcriptionally regulated by NRF2 and iron regulatory proteins, and its activity is influenced by heme availability. The transporter interacts directly with ferrochelatase, the terminal enzyme of heme synthesis, and collaborates with mitoferrin to maintain mitochondrial iron homeostasis. By modulating heme supply, ABCB6 affects the activity of hemoproteins such as cytochromes, globins, and enzymes involved in iron-sulfur cluster biogenesis. Disruption of ABCB6 thus perturbs heme homeostasis, potentially impairing respiratory chain function and altering the expression of downstream heme-dependent factors.
In the Jurkat T-cell leukemia model, ABCB6 knockout provides a unique tool to dissect the role of mitochondrial heme trafficking in cancer cell proliferation and drug resistance. ABCB6 expression has been associated with multidrug resistance, particularly through its involvement in porphyrin-based drug efflux. Loss of ABCB6 may sensitize cells to chemotherapeutics such as doxorubicin or mitoxantrone, offering a platform for studying resistance mechanisms. Additionally, ABCB6 mutations are linked to dyskeratosis congenita and Lan blood group antigen expression, making this model relevant for hematological disease research. The interplay between heme metabolism and T-cell signaling can be examined under conditions of disrupted ABCB6 function, providing insights into metabolic adaptations in leukemia.
Typical applications include heme quantification assays, Western blot analysis of heme biosynthetic enzymes, and RT-qPCR profiling of genes such as ALAS, ALAD, or ferrochelatase. Drug sensitivity can be assessed via MTT viability assays, while flow cytometry with mitochondrial potential-sensitive dyes enables monitoring of mitochondrial health. This polyclonal knockout cell population is suitable for investigations into porphyria, iron-sulfur cluster biogenesis, and mitochondrial homeostasis. Researchers can employ these cells for functional complementation studies, CRISPR-based double-knockout models, or high-throughput screening of compounds targeting heme pathways. For additional technical details or ordering assistance, please contact Ascent Research.
